Amgen Focuses On Its Next Blockbuster: Emerging Markets
This article was originally published in PharmAsia News
Amgen is expected to announce a JV in Japan soon, the company said during a business strategy meeting last week. It expects China, Japan and other emerging markets to bring in roughly $1 billion more in revenue by 2015.
You may also be interested in...
Amgen revealed plans to develop and launch biosimilar versions of Abbott’s Humira and Johnson & Johnson’s Remicade – two competitors to its blockbuster anti-TNF Enbrel – during an investor meeting in New York City Feb. 7.
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say
Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion